CRISPR Therapeutics stock snapshot and recent performance CRISPR Therapeutics (CRSP) has drawn investor attention after its recent trading, with the stock last closing at US$57.69 and posting a 0.5% ...

The gene editing treatment targets the relatively common 1717-1G>A splicing mutation, which does not respond to many current CF therapies.

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $56.42, moving +1.58% from the previous trading session. The stock exceeded the S&P 500, which registered a gain of 1.05% for the ...

Before seedlings can photosynthesize, they depend on fatty acids—and on peroxisomes to process them. Researchers discovered ...

Researchers at LMU have developed a human cell model that replicates key mechanisms of neurodegenerative diseases—with potential for novel therapies. The paper is published in the journal Science ...

Researchers engineered a panel of drug-resistant NSCLC models using CRISPR gene editing and gene overexpression techniques.

A trio of common amino acids may hold the key to unlocking far more powerful gene therapies. Researchers found that adding ...

Is RYTM a good stock to buy? We came across a bearish thesis on Rhythm Pharmaceuticals, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bears’ thesis on RYTM. Rhythm ...

For years, AI drug discovery has been judged on benchmark performance. Now, a set of studies shows what happens when those ...

To accelerate discovery, scientists from ATCC and the Broad Institute collaborated to engineer a panel of drug-resistant NSCLC models using CRISPR gene editing and gene overexpression techniques.